RIGEL PHARMACEUTICALS INC (RIGL)
Health Care · Oncology and hematology-focused biopharmaceuticals · NASDAQ
Rigel is a commercial-stage biotech with three FDA-approved, niche oncology/hematology drugs generating strong revenue growth and a clinical pipeline of novel kinase inhibitors for rare blood disorders and cancers.
What RIGEL PHARMACEUTICALS INC does
Rigel Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for hematologic disorders and cancer. The company focuses on products targeting signaling pathways critical to disease mechanisms, with three FDA-approved products: TAVALISSE (fostamatinib) for chronic ITP, REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive NSCLC and thyroid cancer. The company also has a clinical development pipeline including R289, a dual IRAK1/4 inhibitor for lower-risk MDS.
Themes: ["Hematologic oncology / blood disorders","Targeted cancer therapies","SYK inhibitors / kinase inhibitors","Rare blood cancers (ITP, AML, MDS)","RET-targeted therapy","IDH1 mutation-driven tumors"]
Fundamentals
- Price$43.76 as of 2026-07-09 close
- Market cap$807M as of 2026-07-10
- 1-year return+129.8% as of 2026-07-09 close
- P/E2.22 as of 2026-07-10
- Net margin+121.5% as of 2026-07-10
- Gross margin+93.4% as of 2026-07-10
- ROE+147.0% as of 2026-07-10
- Debt / equity0.11 as of 2026-07-10
- Revenue growth (YoY)+47.6% as of 2026-07-10
- Revenue CAGR (3y)+34.8% SEC XBRL
- Beta1.18 as of 2026-07-10
Key risks (from latest filing)
["Regulatory risk: FDA, EMA, MHRA or other regulatory authorities may make adverse decisions regarding product approvals, commercialization, or ongoing compliance for TAVALISSE, REZLIDHIA, GAVRETO and pipeline products","Commercialization and market adoption risk: Success depends on effective distribution, marketing, and payer acceptance for multiple products in niche oncology/hematology indications","Clinical development risk: R289 and other pipeline programs depend on successful completion of Phase 1b and future Phase 2 studies, with failure to achieve safety/efficacy endpoints or enroll sufficient patients potentially delaying or preventing commercialization"]
Competitors & peers
- Incyte Corporation
- Celgene Corporation
- Alexion Pharmaceuticals
- Agios Pharmaceuticals
- Blueprint Medicines
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.